Physician

Samer Shihabi, M.D.

According to 2025 Medicare claims, Samer Shihabi, M.D. (NPI: 1730110768) practices hematology/oncology in the Sacramento-Roseville-Folsom, CA market, with the plurality of this provider's patient population coming from Sacramento, CA. This provider's primary affiliated billing organization is DIGNITY HEALTH MEDICAL FOUNDATION (NPI: 1700803418; TIN: 770359115) and primary practice location at 95816-3372. Shihabi is affiliated with the CommonSpirit ACO I (ACO ID: A2164), participating under the MSSP model.

Shihabi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 609 traditional Medicare patients, billed 82,513 HCPCS/CPT codes, and received $2,052,680 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 2,002 prescription claims across 359 beneficiaries totaling $6,173,722 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 51 claims. Open Payments data shows 3 records totaling $394. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,533,535 to $6,173,722. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	496	73,496	$1,182,438
2016	452	57,540	$1,042,003
2017	567	84,995	$1,862,801
2018	600	83,886	$1,859,153
2019	587	113,811	$2,016,377
2020	590	110,296	$1,932,947
2021	600	84,468	$2,086,109
2022	583	88,275	$1,850,370
2023	647	76,698	$1,621,591
2024	609	82,513	$2,052,680

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	149	748	$1,533,535
2016	153	897	$1,583,793
2017	204	1,062	$1,546,736
2018	200	1,233	$2,917,249
2019	244	1,602	$4,383,224
2020	257	1,463	$3,935,001
2021	241	1,467	$3,791,109
2022	248	1,359	$3,067,693
2023	312	1,758	$4,124,584
2024	359	2,002	$6,173,722

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	63	$21,583
2016	N/R	22	$10,058
2017	N/R	28	$11,644
2018	N/R	38	$5,186
2019	N/R	40	$5,435
2020	N/R	27	$2,152
2021	N/R	80	$3,595
2022	13	68	$2,461
2023	N/R	51	$12,766
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	83	83	$190
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	185	460	$109
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	301	438	$71
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	76	169	$57
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	246	548	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	40	1,113	$745,031
Venclexta	Venetoclax	34	1,002	$474,721
Lenvima	Lenvatinib Mesylate	18	540	$446,510
Tagrisso	Osimertinib Mesylate	25	750	$416,932
Ibrance	Palbociclib	26	728	$410,573

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$44	US Oncology Corporate, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$350	Novocure Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Samer Shihabi, M.D.?

Tedicare shows public-source Medicare data for Samer Shihabi, M.D. (NPI 1730110768), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Samer Shihabi, M.D. have ACO affiliation data?

Samer Shihabi, M.D. is shown with ACO affiliation data for CommonSpirit ACO I (MSSP, ACO ID A2164).

What billing organization is linked to Samer Shihabi, M.D.?

Samer Shihabi, M.D. is linked to DIGNITY HEALTH MEDICAL FOUNDATION (billing NPI 1700803418) in the available physician profile data.

Does Samer Shihabi, M.D. have Open Payments data?

Samer Shihabi, M.D. has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.